Santen Pharmaceutical Co (JP:4536) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Santen Pharmaceutical Co., Ltd. has completed a buyback of 2,857,200 common shares for a total of 4.9 billion yen between August 1 and August 31, 2024. This move is part of a larger buyback plan announced on May 9, 2024, which aims to repurchase up to 21.11 million shares, representing 5.8% of outstanding shares, with a maximum budget of 38 billion yen by November 6, 2024. To date, Santen has repurchased 12.83 million shares for about 21.25 billion yen, as part of its commitment to enhancing shareholder value and investing in eye health.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.
